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Abstract
Background: In high-income settings, the spectrum of morbidity and mortality experienced by Human Immunodeficiency
Virus (HIV)-infected individuals receiving combination antiretroviral therapy (cART) has switched from predominantly
AIDS-related to non-AIDS-related conditions. In the context of universal access to care, we evaluated whether that shift
would apply in Brazil, a middle-income country with universal access to treatment, as compared to France.
Methods: Two hospital-based cohorts of HIV-infected individuals were used for this analysis: the ANRS CO3 Aquitaine
Cohort in South Western France and the Evandro Chagas Research Institute (IPEC) Cohort of the Oswaldo Cruz
Foundation in Rio de Janeiro, Brazil. Severe morbid events (AIDS- and non-AIDS-related) were defined as all clinical
diagnoses associated with a hospitalization of ≥48 hours. Trends in the incidence rate of events and their determinants
were estimated while adjusting for within-subject correlation using generalized estimating equations models with an
auto-regressive correlation structure and robust standard errors.
Result: Between January 2000 and December 2008, 7812 adult patients were followed for a total of 41,668 person-
years (PY) of follow-up. Throughout the study period, 90% of the patients were treated with cART. The annual incidence
rate of AIDS and non-AIDS events, and of deaths significantly decreased over the years, from 6.2, 21.1, and 1.9 AIDS,
non-AIDS events, and deaths per 100 PY in 2000 to 4.3, 14.9, and 1.5/100 PY in 2008. The annual incidence rates of
non-AIDS events surpassed that of AIDS-events during the entire study period. High CD4 cell counts were associated
with a lower incidence rate of AIDS and non-AIDS events as well as with lower rates of specific non-AIDS events, such
as bacterial, hepatic, viral, neurological, and cardiovascular conditions. Adjusted analysis showed that severe morbidity
was associated with lower CD4 counts and higher plasma HIV RNAs but not with setting (IPEC versus Aquitaine).
Conclusions: As information on severe morbidities for HIV-infected patients remain scarce, data on hospitalizations are
valuable to identify priorities for case management and to improve the quality of life of patients with a chronic disease
requiring life-long treatment. Immune restoration is highly effective in reducing AIDS and non-AIDS severe morbid
events irrespective of the setting.
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Background
Currently, individuals infected by the human immuno-
deficiency virus (HIV) and treated with combination
antiretroviral therapy (cART) live longer than ever in
high-income countries [1]. The spectrum of the disease
has switched in this environment from predominantly
AIDS-related mortality and morbidity to non-AIDS-
related conditions, especially severe infections, end-stage
liver disease, cardiovascular disease, and malignancies
[2-5]. In Brazil, a middle-income country with widely
available cART, AIDS-related conditions remain an im-
portant cause of mortality and morbidity, while an in-
creased representation of non-AIDS defining conditions
has recently been reported [6,7].
Whereas causes of death are now well described [2,4],
severe morbidity has been more difficult to accurately
study and data remain scarce about their distribution
and determinants over time. Observational hospital-
based cohorts from Europe and North America have re-
ported causes of hospitalization in the cART era as a
proxy for severe morbidity, especially in the context of
universal access to care. Indeed, updated information on
severe disease burden can inform HIV clinicians as to
the necessary efforts for screening and prevention and
can be used for monitoring patients with organ-specific
specialists. Policy-makers can also use such information
to project future areas of care needs and associated
costs. Observational hospital-based cohort studies have
shown that HIV-infected individuals continue to be
hospitalized at high rates [3,8,9], with a shift towards
non-AIDS severe morbid events [10]. Despite the fast
evolution of cART coverage including in resource-
constrained settings, there have been only few reports
from these areas over the past ten years. Severe morbidity
in resource-limited settings might also be characterized by
the same shift towards non-AIDS events, though patients
are exposed to specific tropical infectious diseases [11].
Our aim was to describe and contrast severe morbidity
trends and determinants among HIV-infected individ-
uals followed in two geographically contrasting settings
(France and Brazil) with universal access to treatment
and care. To this end, we studied severe morbidity over
a 9-year period in two hospital-based cohorts of HIV-
infected individuals: the ANRS C03 Aquitaine (Aquitaine)
in South Western France and the Evandro Chagas Re-
search Institute (IPEC) Cohort of the Oswaldo Cruz Foun-
dation in Rio de Janeiro, Brazil.
Methods
Study population
The ANRS CO3 Aquitaine Cohort is an open prospect-
ive cohort of HIV-1 infected patients followed in nine
public hospitals of the Aquitaine region in Southwestern
France. The cohort was initiated in 1987 and includes
adults with documented HIV infection regardless of clin-
ical stage and informed consent. Details of the cohort
can be found elsewhere [12]. The ANRS CO3 Aquitaine
Cohort was approved by the French Commission Natio-
nale de L'Informatique et des Libertés (88–84, 88–142,
DR-2010-109). Participants provided written informed
consent and the study is conducted in compliance with
the Helsinki Declaration.
The Evandro Chagas Clinical Research Institute (IPEC)
has provided care to HIV-infected patients in Rio de
Janeiro since 1986. An observational, longitudinal, clin-
ical database has been maintained on patients receiving
primary HIV care in the clinic since 1998. Longitudinal
data are updated regularly using outpatient and inpatient
clinical documentation, laboratory testing results, and
pharmacy records. Prescription of cART (drug, dates of
use, and dose) is documented by the medical provider
and support staff in the clinical records. Trained abstrac-
tors record all this information onto standardized forms
for processing. Details of the cohort have been described
elsewhere [13]. The IPEC cohort was approved by the
Evandro Chagas Clinical Research Ethics Committee
(043/2010, 0032.0.009.000-10). Participants provided writ-
ten informed consent and the study is conducted in com-
pliance with the Helsinki Declaration.
The sample selected for this analysis included all adult
patients (age ≥ 18 years) followed in each cohort from
2000 to 2008.
Definitions
A severe morbid event was defined as a clinical diagno-
sis associated with a hospitalization with at least 48 hours
of duration. For each hospitalization, all diagnosis listed
in the hospital records at hospitalization discharge were
counted as separate severe morbid events. That is, one
hospitalization could be associated with several clinical
diagnoses, and, in this case, each different diagnosis was
taken into account. Dates of admission and discharge
were captured among both discharged patients and
those who died during hospital stay.
The ANRS C03 Aquitaine Cohort used a simplified
version of the International Classification of Diseases
(ICD-10) and the IPEC Cohort used ICD-10 to code the
clinical diagnoses. As some codes could correspond to
several disease categories, we considered a hierarchical
classification with a decreasing order of priority consid-
ering AIDS-events, non-AIDS malignancies, infections
and systemic events. Signs and syndromes were consid-
ered as events if they were not reported along with other
diagnoses during a specific hospitalization. Hospitaliza-
tions due to a non-morbid cause (check-ups, chemother-
apy, drug withdrawal programme, and more generally Z
codes of the ICD-10 classification), whatever the dur-
ation of the stay, were not considered in our definition
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of severe morbidity and were not included in this ana-
lysis. All events retrieved from the database were
reviewed and validated by two clinicians highly experi-
enced in the management of HIV infection, one clinician
from Brazil and another from France. The lists of codes
allocated to the different disease categories by each co-
hort were then compared and all discrepancies were dis-
cussed until a consensus was reached.
Severe morbid events were classified under 22 disease
categories as follows: (1) AIDS, (2) Non-AIDS malignan-
cies, (3) In situ malignancies, (4) Cardiovascular, (5)
Hepatic, (6) Digestive, (7) Psychiatric, (8) Hematological,
(9) Renal, (10) Endocrine, (11) Bacterial, (12) Viral, (13)
Parasitic, (14) Dermatological, (15) Gynecological, (16)
Neurological, (17) Ophthalmological, (18) Respiratory,
(19) Rheumatologic, (20) Trauma, (21) Signs and syn-
dromes, and (22) Other.
Age from birth was updated yearly for each partici-
pant. Presumed mode of HIV exposure was classified as
men who have sex with men (MSM), injection drug use
(IDU), heterosexual transmission, other, and unknown.
Yearly CD4 cell counts and plasma HIV RNAs were de-
fined as the mean value of all measurements taken in a
specific calendar year. CD4 cell counts were categorized
into >500, 500–351, 350–201, 200–51, ≤ 50 cells/mm3.
For consistency across years, 400 copies/ml of plasma
HIV RNA was defined as the limit of detection. Plasma
HIV RNA was categorized into ≤ 400, 401–3000, 3001–
10000, 10001–100000, >100000 copies/ml. Time since
first HIV positive test was calculated for each calendar
year. cART was defined as two nucleoside reverse tran-
scriptase inhibitors plus either one non-nucleoside re-
verse transcriptase inhibitor or one protease-inhibitor
(boosted or not). Hepatitis B infection was defined by
the presence of hepatitis B surface antigen (HBsAg)
while hepatitis C infection was defined by the presence
of hepatitis C antibodies.
Analyses
Descriptive analyses of the demographic and clinical char-
acteristics of the study patients were conducted, including
age, gender, mode of HIV transmission, CD4 cell count,
plasma HIV RNA, time since first HIV positive test, ever
use of cART, and hepatitis B and C co-infections.
Each patient contributed to multiple years of observa-
tion, one for each calendar year. Patients could enroll in
the cohort at any time preceding or during the study
period (1 January 2000 to 31 December 2008), and thus
the number of person-years was not constant across pa-
tients or years. Within each year, we calculated the num-
ber of days of follow-up. If a patient enrolled in a given
year, the number of days prior to enrolment was ex-
cluded from the count of number of days of follow up
for that year. Individuals were not censored after an
episode of hospitalization, that is, readmissions were also
studied, irrespective of the reason for hospitalization.
The end of follow-up was defined as the last contact
with the clinic, 31 December 2008, or death, whichever
occurred first.
We estimated the rate of severe morbid events overall
and by category for each calendar year using as numer-
ator the number of severe morbid events and as denom-
inator the person-years (PY) of follow-up. To assess
trends over time, calendar year (2000 to 2008) was in-
cluded in the regression model and the significance of
the per year increase coefficient was tested. Age, CD4
cell count, plasma HIV RNA, time since first HIV posi-
tive test, ever use of cART, and hepatitis B and C co-
infection were updated for each year of follow-up.
Adjusted incidence rate ratios were used to measure the
degree of association of demographic and clinical factors
with the overall incidence rate of AIDS, death, and non-
AIDS events, as well as the specific incidence rate of
non-AIDS events categories.
We used generalized estimating equations (GEE)
models with an auto-regressive correlation matrix and
robust standard errors to adjust for the clustered nature
of the data here represented by the multiple observation
years for each patient (assumption of independence be-
tween clusters). The specified working correlation struc-
ture (i.e. the auto-regressive correlation matrix) describes
how the responses (annual rate of events) within clusters
(patients) are related to each other. GEE models have been
extensively used for data in which the responses are corre-
lated [14,15]. The R Project for Statistical Computing
(version 2.15.2) was used for all analyses.
Results
Between January 2000 and December 2008, 7812 pa-
tients were followed for a total of 41,668 person-years
(PY) of follow-up, 29,866 PY for Aquitaine and 11,802
PY for IPEC. The mean follow-up time per patient for
the two cohorts combined was 5.3 years (median
5.4 years, interquartile range [IQR] 2.3-9.0 years). Ap-
proximately two-thirds of the study population was from
Aquitaine and its mean follow-up time per patient was
6.0 years (median 6.9 years, IQR 3.2-9.0 years), com-
pared to 4.2 years (median 3.3 years, IQR 1.4-7.4 years)
for IPEC.
Demographic and clinical characteristics of the study
population varied over time (Table 1). The proportion of
patients in the age groups 50–59 and ≥ 60 years of age
increased from 9.2% and 4.2% in 2000 to 17.8% and 8.2%
in 2008, respectively. The relative frequency of heterosex-
ual contact as the mode of HIV transmission increased
while injection drug use decreased over time. Patients’ im-
munological profile at a given year significantly improved
with time and half of the study population reaching a CD4
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cell count >500 cells/mm3 in 2008; in addition two-thirds
of the population had undetectable plasma HIV RNA in
2008. The prevalence of hepatitis C decreased over time.
Ageing, decreased proportion of IDUs, and improved im-
munological profile were observed in the two cohorts
when evaluated separately, though trends were more
Table 1 Demographic and clinical characteristics (number [percent]) of the study population by year, ANRS CO3 Aquitaine
and IPEC/FIOCRUZ cohorts combined
2000 2001 2002 2003 2004 2005 2006 2007 2008
Number of patients 3911 4165 4375 4568 4898 5267 5621 5916 6144
Age in yearsa
< 30 430 (11.0) 419 (10.1) 364 (8.3) 336 (7.4) 325 (6.6) 384 (7.3) 426 (7.6) 456 (7.7) 483 (7.9)
30-39 1830 (46.8) 1808 (43.4) 1787 (40.8) 1690 (37) 1614 (33) 1563 (29.7) 1501 (26.7) 1494 (25.3) 1462 (23.8)
40-49 1127 (28.8) 1316 (31.6) 1505 (34.4) 1715 (37.5) 1987 (40.6) 2183 (41.4) 2422 (43.1) 2547 (43.1) 2603 (42.4)
50-59 359 (9.2) 435 (10.4) 518 (11.8) 597 (13.1) 700 (14.3) 811 (15.4) 905 (16.1) 982 (16.6) 1093 (17.8)
> = 60 165 (4.2) 187 (4.5) 201 (4.6) 230 (5) 272 (5.6) 326 (6.2) 367 (6.5) 437 (7.4) 503 (8.2)
Gender
Male 2725 (69.7) 2879 (69.1) 3039 (69.5) 3175 (69.5) 3418 (69.8) 3679 (69.9) 3898 (69.3) 4096 (69.2) 4256 (69.3)
Mode of HIV transmissionb
Heterosexual 1129 (28.9) 1274 (30.6) 1371 (31.3) 1464 (32) 1613 (32.9) 1798 (34.1) 1994 (35.5) 2176 (36.8) 2328 (37.9)
MSM 1383 (35.4) 1471 (35.3) 1575 (36) 1682 (36.8) 1817 (37.1) 1963 (37.3) 2102 (37.4) 2221 (37.5) 2320 (37.8)
IDU 1011 (25.9) 996 (23.9) 984 (22.5) 955 (20.9) 965 (19.7) 947 (18) 933 (16.6) 909 (15.4) 858 (14)
Other 145 (3.7) 150 (3.6) 151 (3.5) 155 (3.4) 155 (3.2) 157 (3) 165 (2.9) 161 (2.7) 166 (2.7)
Unknown 243 (6.2) 274 (6.6) 294 (6.7) 312 (6.8) 348 (7.1) 402 (7.6) 427 (7.6) 449 (7.6) 472 (7.7)
CD4 cell countc
> 500 1306 (38.3) 1412 (39.5) 1580 (41) 1646 (41.9) 1768 (40.7) 1996 (41.9) 2274 (44.9) 2457 (45.3) 2720 (47.2)
351-500 787 (23.1) 866 (24.2) 920 (23.9) 924 (23.5) 1075 (24.7) 1167 (24.5) 1225 (24.2) 1375 (25.4) 1453 (25.2)
201-350 777 (22.8) 783 (21.9) 795 (20.6) 852 (21.7) 931 (21.4) 963 (20.2) 997 (19.7) 985 (18.2) 1017 (17.7)
51-200 427 (12.5) 410 (11.5) 449 (11.7) 414 (10.5) 446 (10.3) 502 (10.5) 459 (9.1) 501 (9.2) 479 (8.3)
<= 50 114 (3.3) 107 (3) 107 (2.8) 94 (2.4) 128 (2.9) 132 (2.8) 115 (2.3) 103 (1.9) 93 (1.6)
Plasma HIV RNAc
<= 400 1151 (33.8) 1324 (37.3) 1628 (42.3) 1859 (47.3) 2100 (48.8) 2514 (53.5) 2908 (58.5) 3348 (63.1) 3898 (68.4)
401-3000 749 (22) 795 (22.4) 689 (17.9) 598 (15.2) 613 (14.3) 604 (12.8) 557 (11.2) 511 (9.6) 518 (9.1)
3001-10000 475 (13.9) 451 (12.7) 445 (11.6) 409 (10.4) 393 (9.1) 396 (8.4) 345 (6.9) 354 (6.7) 318 (5.6)
10001-100000 725 (21.3) 716 (20.2) 781 (20.3) 789 (20.1) 871 (20.3) 862 (18.3) 787 (15.8) 805 (15.2) 721 (12.6)
> 100000 308 (9) 267 (7.5) 306 (8) 277 (7) 323 (7.5) 325 (6.9) 378 (7.6) 288 (5.4) 246 (4.3)
≤ 1 year since first HIV + testd
Yes 439 (11.2) 350 (8.4) 337 (7.7) 316 (6.9) 316 (6.5) 421 (8.0) 493 (8.8) 496 (8.4) 501 (8.2)
On cARTe
Yes 3506 (89.6) 3724 (89.4) 3932 (89.9) 4101 (89.8) 4393 (89.7) 4684 (88.9) 4913 (87.4) 5197 (87.8) 5508 (89.6)
Hepatitis Bf
Yes 215 (6.1) 235 (6.2) 249 (6.2) 258 (6.1) 280 (6.2) 305 (6.3) 331 (6.4) 348 (6.4) 367 (6.6)
Hepatitis Cg
Yes 949 (26.7) 968 (25.5) 1013 (25.2) 1022 (24.2) 1027 (22.6) 1008 (20.5) 1018 (19.4) 999 (18.2) 978 (17.3)
aAge from birth was updated yearly for each participant.
bPresumed mode of HIV exposure was classified as men who have sex with men (MSM), injection drug use (IDU), heterosexual transmission, other, and unknown.
cYearly CD4 cell counts and plasma HIV RNAs were defined as the mean value of all measurements taken in a specific calendar year.
dTime since first HIV + test was calculated for each calendar year.
eCombination antiretroviral therapy (cART) was defined as two nucleoside reverse transcriptase inhibitors plus either one non-nucleoside reverse transcriptase
inhibitor or one protease-inhibitor (boosted or not).
fHepatitis B infection was defined by the presence of hepatitis B surface antigen (HBsAg).
gHepatitis C infection was defined by the presence of hepatitis C antibodies.
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pronounced in the Aquitaine Cohort (see Additional file 1:
Tables S1 and S2). In IPEC, an increased proportion of
males was observed over time. Throughout the study
period, the proportion of patients diagnosed with HIV in-
fection for less than one year remained stable (10%), as
was the use of cART (90%), and the co-infection with
hepatitis B virus (6%).
During the entire study period, hospitalization for a
severe morbid event occurred in a pool of 2238 (28.6%)
participants, 1473 (29.5%) from Aquitaine and 765
(27.1%) from IPEC. A total of 4689 hospitalizations were
recorded, 3049 (65.0%) in Aquitaine and 1640 (35.0%) in
IPEC. One severe morbid event was reported in 2348
hospitalizations (50.1%), two morbid events in 1359 hos-
pitalizations (29.0%), and three in 599 hospitalizations
(12.8%). In 383 (8.2%) hospitalizations more than three
severe morbid events were reported. Among those who
were hospitalized (2238/7812, 28.6%), 8696 severe mor-
bid events were reported, 5963 (68.6%) in Aquitaine and
2733 (31.4%) in IPEC. There were 310 deaths reported, a
6.6% fatality ending hospitalizations.
Over the entire study period, the incidence rate of se-
vere morbid events was 21.5/100 PY (95% confidence
interval (95% CI): 20.3 to 22.8/100 PY) overall, 20.5/100
PY (95% CI 19.1 to 22.0/100 PY) in Aquitaine and 24.0/
100 PY (95% CI 21.8 to 26.4/100 PY) in IPEC. The an-
nual incidence rate of severe morbid events significantly
decreased from 27.3/100 PY in 2000 to 19.2/100 PY in
2008 (p < 0.001, Table 2). This downward trend was ob-
served for both AIDS and non-AIDS events. The annual
incidence rate of non-AIDS events surpassed that of
AIDS-events during the entire study period. These trends
were observed in both cohorts though the ratio of annual
incidence rates of non-AIDS to AIDS events was much
higher in the Aquitaine Cohort (up to 6:1) than in the
IPEC Cohort (always <2:1).
Annual mortality rates also decreased over time. Eight
hundred and ninety one patients died during the study
period yielding a mortality rate that decreased from 1.9/
100 PY in 2000 to 1.5/100 PY in 2008 (p < 0.01). In
Aquitaine, 498 patients died during the study period and
the mortality rate decreased from 1.6/100 PY in 2000 to
1.1/100PY in 2008 (p < 0.01). In IPEC, 393 deaths oc-
curred yielding a higher mortality rate that also de-
creased from 3.0/100 PY in 2000 to 2.3/100 PY in 2008
although the difference did not reach statistical signifi-
cance (p = 0.09).
The annual incidence rates of the 21 non-AIDS disease
categories are displayed in Table 3. Bacterial infection
was the most frequent cause of non-AIDS events with a
total of 1602 events yielding a stable incidence rate over
time ranging between 3.5 and 4.5 events per 100 PY (p =
0.12). Although similar for each cohort when evaluated
separately (see Additional file 1: Table S3 and Table S4),
the incidence was much higher in IPEC with a maximum
of 9.0 events per 100 PY in 2001 while in Aquitaine the
maximum was 3.9 events per 100 PY in 2000. Following
bacterial infection and by decreasing order of importance,
the following disease categories were: psychiatric diseases,
hepatic diseases, viral, hematological, neurological, digest-
ive, cardiovascular, and parasitic diseases. In Aquitaine,
psychiatric diseases held the second position while cardio-
vascular events were the second most frequent event cat-
egory in IPEC (see Additional file 1: Tables S3 and S4).
Table 2 Annual incidence rates per 100 person-years of severe morbid events, AIDS and non-AIDS events, and deaths,
overall and by cohort (ANRS CO3 Aquitaine and IPEC/FIOCRUZ cohorts)
2000 2001 2002 2003 2004 2005 2006 2007 2008 P-value
Overall
Severe morbid event 27.3 26.4 20.5 21.2 20.3 19.4 18.0 19.1 19.2 < 0.01
AIDS 6.2 5.7 5.0 4.4 5.1 4.6 3.6 3.8 4.3 < 0.01
Non-AIDS 21.1 20.7 15.5 16.7 15.2 14.8 14.4 15.3 14.9 < 0.01
Death 1.9 2.7 2.3 2.2 2.5 2.6 2.0 2.0 1.5 < 0.01
ANRS CO3 Aquitaine
Severe morbid event 26.2 25.2 18.7 18.9 18.7 17.6 17.8 20.0 18.2 < 0.01
AIDS 4.7 4.4 3.1 2.7 2.9 2.5 1.9 2.5 2.0 < 0.01
Non-AIDS 21.6 20.8 15.6 16.2 15.8 15.2 15.9 17.5 16.2 0.04
Death 1.6 2.3 2.2 1.7 1.6 1.9 1.5 1.3 1.1 < 0.01
IPEC/FIOCRUZ
Severe morbid event 31.4 30.5 26.2 27.8 24.6 23.9 18.3 17.3 20.9 < 0.01
AIDS 12.0 10.2 11.1 9.5 10.9 10.1 7.3 6.4 8.2 < 0.01
Non-AIDS 19.4 20.4 15.1 18.3 13.6 13.7 11.0 10.8 12.7 < 0.01
Death 3.0 4.0 2.6 3.6 4.7 4.2 3.0 3.3 2.3 0.09
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Psychiatric, viral, neurological, digestive, parasitic and
dermatological diseases showed a statistically significant
decreasing trend over the study period in the two co-
horts combined (Table 3). The incidence rate of non-
AIDS defining malignancies ranged between 0.1 and
0.5 events per 100 PY but did not decrease over time
(p = 0.73).
The three most frequent diagnoses within the AIDS
category and specific non-AIDS categories are shown in
Table 4 for both cohorts combined and in the Additional
file 1: Table S5 and Table S6 for Aquitaine and IPEC Co-
horts, respectively. Overall and in each cohort, the two
most frequent diagnoses within the AIDS category were
pneumocystosis and toxoplasmosis, while tuberculosis
held the third position overall and in IPEC Cohort but
not in Aquitaine Cohort. Bacterial pneumonia and sepsis
were the most frequent diagnoses within bacterial infec-
tions while among psychiatric diseases the most frequent
diagnoses were depression, drug abuse and anorexia.
Overall, the top three diagnoses within cardiovascular
diseases were hypertension, thrombosis, and cerebral in-
farction. Lung cancer and Hodgkin lymphoma were
among the most frequent diagnoses within the non-
AIDS malignancy category.
Adjusted incidence rate ratios quantifying the degree
of association of demographic and clinical factors with
the incidence rate of AIDS and non-AIDS events are
shown in Table 5. Immunodeficiency was found to be
associated with the severe morbid events. As expected,
the association with low CD4 cell count was strong for
AIDS events with a dose–response pattern. Albeit the
magnitude of the association was smaller, lower CD4 cell
counts were also associated with a higher incidence rate
of non-AIDS events, of specific non-AIDS events, and of
deaths (Table 5). Higher plasma HIV RNA, less than
1 year since first HIV positive test and use of cART were
significantly associated with a higher incidence rate of
AIDS events.
The incidence of non-AIDS events was increased for
those with older age and who reported injection drug use.
The incidence of non-AIDS events was also significantly
higher for those with less than 1 year since first HIV posi-
tive test, those who used cART, and those with hepatitis C
co-infection. Of note is the fact that, even after adjusting
for confounders, IPEC still showed a lower incidence of
non-AIDS events when compared to Aquitaine.
Age ≥ 60 years was associated with a higher incidence
rate of several specific non-AIDS events categories,
Table 3 Annual incidence rates per 100 person-years of non-AIDS events ranked from most to least frequent (ANRS CO3
Aquitaine and IPEC/FIOCRUZ cohorts combined)
2000 2001 2002 2003 2004 2005 2006 2007 2008 P-value Total #
of events
1 Bacterial 4.50 4.35 3.69 3.93 3.91 3.52 3.65 3.73 3.64 0.12 1602
2 Psychiatric 2.39 1.89 1.64 1.70 2.09 1.69 1.85 1.42 1.34 < 0.01 727
3 Hepatic 1.21 1.97 1.12 1.14 1.29 1.56 1.37 1.35 1.36 0.61 572
4 Viral 2.33 1.32 1.51 1.16 1.14 0.95 0.69 0.71 1.06 < 0.01 481
5 Hematological 0.90 1.63 1.27 1.23 1.34 1.01 1.00 0.93 1.15 0.51 479
6 Neurological 1.40 1.89 1.10 1.30 0.94 1.07 0.79 0.60 0.99 < 0.01 450
7 Digestive 1.70 1.48 0.88 1.21 0.86 0.99 1.00 0.76 0.79 < 0.01 433
8 Cardiovascular 0.93 1.19 0.76 0.91 0.70 0.64 0.88 0.98 1.10 0.82 375
9 Parasitic 1.15 0.83 0.66 1.07 0.79 0.49 0.52 0.66 0.49 < 0.01 298
10 Signs/syndromes 0.90 0.67 0.24 0.40 0.40 0.60 0.42 0.73 0.35 0.32 215
11 Renal 0.63 0.26 0.51 0.35 0.37 0.45 0.44 0.76 0.49 0.26 201
12 Rheumatologic 0.41 0.39 0.37 0.21 0.22 0.39 0.46 0.62 0.39 0.24 163
13 Endocrine 0.44 0.57 0.22 0.42 0.44 0.47 0.23 0.42 0.30 0.33 160
14 Respiratory 0.63 0.44 0.56 0.37 0.15 0.23 0.25 0.49 0.41 0.22 160
15 Dermatological 0.58 0.52 0.39 0.47 0.26 0.29 0.27 0.35 0.25 < 0.01 150
16 Malignancies 0.36 0.47 0.17 0.51 0.09 0.16 0.29 0.38 0.46 0.73 134
17 Other 0.44 0.34 0.27 0.23 0.13 0.14 0.06 0.20 0.11 < 0.01 83
18 Ophthalmological 0.08 0.39 0.02 0.02 0.09 0.02 0.08 0.09 0.11 0.22 40
19 Trauma 0.08 0.00 0.10 0.02 0.00 0.04 0.13 0.05 0.11 0.25 26
20 Gynecological 0.03 0.08 0.02 0.02 0.02 0.06 0.00 0.02 0.04 0.52 13
21 In situ neoplasia 0.03 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 NA 2
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including bacterial, hepatic, neurological, and cardiovas-
cular. Age ≥ 60 years showed a particularly strong associ-
ation with cardiovascular disease (adjusted incidence
rate ratio 5.27 95% CI: 2.14-12.93, Table 5). Injection
drug use was associated with a higher incidence of
psychiatric and neurological events. One year or less
since first HIV positive test was significantly positively
associated with the incidence of parasitic diseases. Hepa-
titis C co-infection was significantly associated with an
increased incidence of hepatic diseases (adjusted inci-
dence rate ratio 5.18 95% CI: 3.29-8.14).
Mortality was significantly higher with increasing age,
decreasing immunity, increased plasma HIV RNA, and
the presence of hepatitis B or C co-infection (Table 5).
Discussion
We report here a unique analysis of multi-morbidity pat-
terns among HIV-infected individuals followed in two
geographically contrasting settings (Europe and South
America) with universal access to treatment and care in
the cART era. Over a 9-year period (2000–2008), ageing,
decreased representation of IDUs, and improved im-
munological profile were observed in both cohorts
largely exposed to cART. The rate of severe morbid
events decreased by one-third over the period and, in
2008, only one out of five events was AIDS-related; non-
AIDS events were always more frequent than AIDS
events. Immunodeficiency was associated with a higher
incidence of AIDS-related and all types of non-AIDS-
related events. Our observations suggest that long-term
restoration and preservation of high CD4 cell counts as
a result of cART access is highly and durably effective in
preventing AIDS as well as non-AIDS severe morbid
events.
In this collaboration, sizeable efforts were allocated for
the collection, documentation and uniform classification
and coding of morbid events leading to hospitalizations.
There is indeed a lack of published studies on the long-
term causes of severe morbidity leading to hospitaliza-
tion in HIV-infected patients, although such information
is highly valuable in identifying priorities for case man-
agement and improvement of the quality of life of sub-
jects living with a chronic disease requiring life-long
treatment. Our study population combined two hospital-
based cohorts that mainly differed by environment and
only modestly by access to care. In this context, non-
AIDS related conditions were the most common cause
of hospitalizations throughout the study period.
The decreasing incidence rate of AIDS-related events
over time confirms the improvements in HIV care as
this finding is accompanied by a higher percentage of in-
dividuals with CD4 cell counts >500 cells/mm3 and un-
detectable plasma HIV RNAs. In fact, even beyond
severe immunodeficiency, individuals with CD4 cell
counts between 350–500 cells/mm3 were found to have
a three times higher incidence rate of AIDS events than
those with CD4 cell counts >500 cells/mm3. In addition,
although the comparison of the incidence rate of AIDS
events in Aquitaine and IPEC initially suggested that
Table 4 Three most frequent diagnoses within the AIDS
and specific non-AIDS severe morbid events categories
(ANRS CO3 Aquitaine and IPEC/FIOCRUZ cohorts combined,
2000–2008)
Diagnosis (ICD-10 code) N/Total N (%)
AIDS
Pneumocystosis (B59) 278/1932 (14.4)
Toxoplasmosis (B58.2) 161/1932 (8.3)
Tuberculosis (A15.3) 146/1932 (7.6)
Non-AIDS
Bacterial
Bacterial pneumonia (J15.9) 289/1602 (18.0)
Sepsis (A41.9) 204/1602 (12.7)
Pneumonia, other specified infectious organisms (J16.8) 127/1602 (7.9)
Psychiatric
Depressive episode (F32.9) 190/727 (26.1)
Drug abuse (F19.9) 142/727 (19.5)
Anorexia (R63.0) 73/727 (10.0)
Hepatic
Hepatic failure (K72.9) 100/572 (17.5)
Toxic liver disease with acute hepatitis (K71.2) 85/572 (14.9)
Ascites (R18) 61/572 (10.7)
Viral
Acute bronchitis (J20.9) 71/481 (14.8)
Zoster infection (B02.9) 52/481 (10.8)
Gastroenteritis (A09) 46/481 (9.6)
Neurological
Headache (R51) 76/450 (16.9)
Dizziness (R42) 44/450 (9.8)
Epilepsy (G40.9) 43/450 (9.6)
Cardiovascular
Hypertension (I10) 39/375 (10.4)
Thrombosis (I82.9) 32/375 (8.5)
Cerebral infarction (I63.9) 29/375 (7.7)
Parasitic
Candidal stomatitis (B37.0) 181/298 (60.7)
Mycosis (B49) 23/298 (7.7)
Candidiasis of other sites (B37.8) 9/298 (3.0)
Non-AIDS malignancy
Lung cancer (C34.9) 40/134 (29.9)
Unspecified cancer (C80) 23/134 (17.2)
Hodgkin lymphoma (C81.9) 16/134 (11.9)
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Table 5 Adjusted incidence rate ratios and 95% confidence intervals for factors associated with AIDS-related events,
non-AIDS-related events, and deaths (ANRS CO3 Aquitaine and IPEC/FIOCRUZ cohorts combined, 2000–2008)
AIDS-related Non-AIDS
All Bacterial Psychiatric Hepatic
Cohort: IPEC (vs. Aquitaine) 1.09 (0.91, 1.3) 0.53 (0.46, 0.62) 1.17 (0.94, 1.47) 0.37 (0.24, 0.55) 0.78 (0.52, 1.17)
Calendar year (per year) 1.03 (0.99, 1.06) 1.02 (1.0, 1.05) 1.03 (1.0, 1.07) 1.04 (0.98, 1.09) 1.05 (0.98, 1.12)
Age (in years)
<30 years 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
30-39 0.95 (0.72, 1.26) 1.05 (0.83, 1.33) 1.34 (0.98, 1.83) 1.28 (0.76, 2.17) 0.8 (0.39, 1.65)
40-49 0.81 (0.61, 1.08) 1.12 (0.88, 1.44) 1.18 (0.85, 1.64) 1.18 (0.7, 2.01) 1.52 (0.78, 2.99)
50-59 0.59 (0.42, 0.83) 1.24 (0.94, 1.65) 1.13 (0.78, 1.64) 0.95 (0.5, 1.78) 1.48 (0.67, 3.28)
≥60 0.93 (0.61, 1.4) 2.16 (1.58, 2.97) 1.9 (1.24, 2.89) 1.14 (0.54, 2.38) 3.09 (1.13, 8.49)
Sex: Female (vs. Male) 0.9 (0.76, 1.07) 1.01 (0.88, 1.15) 0.95 (0.79, 1.15) 1.06 (0.81, 1.37) 0.98 (0.63, 1.52)
IDU: Yes (vs. No) 1.03 (0.78, 1.36) 1.42 (1.18, 1.7) 1.01 (0.75, 1.34) 3.14 (2.29, 4.3) 1.49 (0.89, 2.49)
CD4 cell count (cells/mm3)
>500 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
351-500 3.47 (2.19, 5.51) 1.28 (1.07, 1.53) 1.24 (0.95, 1.61) 0.96 (0.67, 1.38) 2.42 (1.44, 4.08)
201-350 9.05 (5.91, 13.88) 2.25 (1.89, 2.67) 1.85 (1.43, 2.4) 1.98 (1.44, 2.73) 4.87 (2.97, 7.99)
51-200 31.83 (20.81, 48.71) 4.34 (3.59, 5.24) 3.94 (2.95, 5.26) 2.59 (1.76, 3.79) 9.52 (5.56, 16.29)
≤50 111.45 (70.13, 177.11) 10.99 (8.66, 13.94) 9.14 (6.37, 13.12) 4.98 (2.96, 8.37) 22.31 (11.27, 44.15)
HIV viral load (copies/mL)
≤400 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
401-3000 1.58 (1.14, 2.17) 1.3 (1.09, 1.54) 1.41 (1.09, 1.83) 1.08 (0.75, 1.57) 1.28 (0.76, 2.17)
3001-10000 1.6 (1.11, 2.29) 1.45 (1.18, 1.76) 1.12 (0.83, 1.52) 1.87 (1.25, 2.81) 1.71 (0.86, 3.4)
10001-100000 2.3 (1.76, 3.01) 1.76 (1.5, 2.06) 1.96 (1.54, 2.49) 2.02 (1.44, 2.84) 1.53 (0.96, 2.43)
>100000 4.39 (3.33, 5.8) 2.61 (2.15, 3.16) 2.79 (2.12, 3.68) 2.89 (1.93, 4.33) 2.18 (1.21, 3.92)
≤1 year since HIV + test: Yes (vs. No) 3.87 (3.19, 4.71) 1.99 (1.69, 2.35) 1.51 (1.16, 1.97) 1.04 (0.65, 1.67) 2.74 (1.84, 4.1)
On cART: Yes (vs. No) 2.15 (1.23, 3.74) 2.5 (1.82, 3.44) 1.58 (1.04, 2.41) 2.21 (1.12, 4.38) 3.72 (1.5, 9.2)
Hepatitis B positive (vs. not) 1.03 (0.77, 1.39) 1.17 (0.93, 1.47) 1.23 (0.9, 1.68) 0.92 (0.57, 1.5) 1.93 (1.16, 3.18)
Hepatitis C positive (vs. not) 0.95 (0.74, 1.23) 1.7 (1.45, 2.0) 1.91 (1.52, 2.4) 1.73 (1.29, 2.32) 5.18 (3.29, 8.14)
Non-AIDS Death
Viral Neurological Cardiovascular Parasitic
Cohort: IPEC (vs. Aquitaine) 0.52 (0.38, 0.7) 0.06 (0.03, 0.12) 1.13 (0.76, 1.68) 0.17 (0.09, 0.3) 1.01 (0.79, 1.28)
Calendar year (per year) 0.95 (0.9, 1.0) 0.96 (0.9, 1.02) 1.01 (0.94, 1.1) 1.04 (0.98, 1.11) 1 (0.96, 1.04)
Age (in years)
<30 years 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
30-39 0.93 (0.6, 1.44) 1.1 (0.55, 2.21) 0.93 (0.39, 2.19) 1.07 (0.59, 1.94) 1.76 (0.92, 3.35)
40-49 0.82 (0.51, 1.31) 1.41 (0.67, 2.93) 1.72 (0.74, 4) 0.89 (0.48, 1.65) 2.18 (1.15, 4.14)
50-59 0.76 (0.44, 1.32) 1.55 (0.72, 3.33) 2.4 (0.99, 5.81) 0.85 (0.43, 1.67) 3.25 (1.69, 6.25)
>60 0.94 (0.47, 1.85) 3.13 (1.41, 6.97) 5.27 (2.14, 12.93) 1.19 (0.42, 3.35) 6.55 (3.32, 12.92)
Sex: Female (vs. Male) 1.26 (0.98, 1.62) 1.04 (0.74, 1.47) 0.94 (0.65, 1.35) 1.2 (0.85, 1.69) 0.66 (0.51, 0.85)
IDU: Yes (vs. No) 1.07 (0.77, 1.48) 2.01 (1.29, 3.12) 1.55 (0.97, 2.46) 1.08 (0.71, 1.64) 1.29 (0.93, 1.78)
CD4 cell count (cells/mm3)
>500 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
351-500 0.81 (0.55, 1.18) 1.48 (0.94, 2.33) 2.00 (1.23, 3.24) 1.79 (0.85, 3.75) 1.44 (0.99, 2.08)
201-350 1.76 (1.25, 2.48) 2.3 (1.52, 3.46) 2.06 (1.22, 3.47) 3.82 (1.88, 7.76) 2.25 (1.6, 3.18)
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AIDS events occurred at much higher frequency in the
latter, after adjustments for other characteristics (im-
munological and virological profile as well as time since
first HIV positive test), this finding did not hold, sug-
gesting that environment is not a primary determinant
of the occurrence of AIDS severe diseases in a popula-
tion highly exposed to effective antiretroviral combina-
tions [16]. Universal access to cART in both settings as
well as more potent and user-friendly cART regimens
readily available along the study period [17-20] have in-
deed contributed to these findings.
Concerning mortality, the results paralleled the ones
described above for AIDS-related events. Determinants
of higher mortality rates were immunodeficiency, high
plasma HIV RNA, ageing and co-infection with hepatitis
B or C, rather than environment. Indeed, these findings
corroborate a previous analysis that showed similar rates
of early mortality between developed and resource-
limited settings when adjusted for immunological and
virological factors [13].
The relative higher incidence of non-AIDS-related
events when compared to AIDS-related events through-
out the study period confirms the recent findings of the
significant burden of non-AIDS events among those liv-
ing with HIV with a shift from AIDS to non-AIDS se-
vere morbidity for the period 2000 to 2004 [10]. A
recent study from the Swiss cohort also showed that
non-AIDS-related events outnumbered HIV-related
events in that setting in the years 2008 through 2010,
and that non-AIDS-related events were associated with
older age, similarly to our results [21]. Our adjusted ana-
lysis showed a lower incidence of non-AIDS events in
the IPEC cohort even after taking into account possible
confounding factors. An explanation for this finding
might be differences in indication for hospitalization in
the two settings. Although the overall rates of non-
AIDS-related events have significantly decreased be-
tween 2000 and 2008, the incidence of bacterial, cardio-
vascular, hepatic and hematological events remained
stable over time. Prevention programs targeting tobacco
use cessation, vaccination against influenza and pneumo-
coccal diseases can greatly impact the most frequent
non-AIDS severe morbid event category, i.e. bacterial in-
fections. As for non-AIDS defining malignancies, existing
screening policies such as anal cancer screening could
be applied and additional screening policies, for example
for lung cancer, should be evaluated.
Bacterial events were by far the most frequent category
with no decreasing trend over the years. A stabilization
was also identified in the most recent analysis of North
American cohorts [3] where a classification system simi-
lar to the one used in the present study was employed.
Differently from HOPS, NHS, or prior HIVRN [8,22],
the study by Berry et al. [3] and the present study classified
infections (bacterial, viral or parasitic) as hierarchically
higher than end-organ categories because antimicrobials
are the primary therapy and many cases require special-
ized case management. In a combined analysis of two co-
horts from Côte d’Ivoire, bacterial events were also among
the most frequent events that led to hospitalization (23%
of all hospitalizations [11]). In the latter study, though dif-
ferently from the present analysis, only a minority of pa-
tients were receiving cART [11]. Hence, bacterial events
do not seem to be impacted by the increase in cART use
and represent an important disease burden especially for
septicemia and septic shock with important costs for
drugs and intensive care units [23]. The high burden of
bacterial infections in our study population indicates an
Table 5 Adjusted incidence rate ratios and 95% confidence intervals for factors associated with AIDS-related events,
non-AIDS-related events, and deaths (ANRS CO3 Aquitaine and IPEC/FIOCRUZ cohorts combined, 2000–2008)
(Continued)
51-200 2.8 (1.9, 4.11) 5.76 (3.58, 9.26) 4.64 (2.66, 8.12) 11.73 (5.9, 23.32) 6.33 (4.5, 8.89)
≤50 9.71 (6.07, 15.52) 13.6 (7.55, 24.49) 15.9 (8.13, 31.28) 29.59 (13.83, 63.28) 27.32 (18.44, 40.47)
HIV viral load (copies/mL)
≤400 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
401-3000 1.38 (0.94, 2.02) 1.51 (0.98, 2.33) 0.91 (0.52, 1.59) 2.22 (1.11, 4.48) 0.91 (0.64, 1.31)
3001-10000 1.65 (1.07, 2.53) 1.91 (1.23, 2.97) 1.13 (0.6, 2.1) 3.09 (1.52, 6.31) 1.03 (0.68, 1.56)
10001-100000 2.52 (1.83, 3.46) 1.63 (1.11, 2.38) 1.18 (0.77, 1.8) 4.88 (2.9, 8.21) 1.08 (0.81, 1.44)
>100000 3.13 (2.1, 4.65) 2.49 (1.59, 3.9) 1.15 (0.67, 1.99) 8.03 (4.51, 14.29) 1.49 (1.07, 2.09)
≤1 year since HIV + test: Yes (vs. No) 2.72 (1.93, 3.83) 1.17 (0.67, 2.03) 1.67 (0.96, 2.93) 4.51 (3.14, 6.47) 0.85 (0.53, 1.37)
On cART: Yes (vs. No) 2.45 (1.3, 4.6) 8.3 (1.95, 35.33) 3.86 (1.17, 12.8) 7.62 (1.75, 33.26) 0.85 (0.5, 1.47)
Hepatitis B positive (vs. not) 0.98 (0.61, 1.59) 1.07 (0.6, 1.91) 1.05 (0.61, 1.8) 1.31 (0.73, 2.37) 1.96 (1.44, 2.66)
Hepatitis C positive (vs. not) 1.11 (0.82, 1.51) 1.02 (0.65, 1.58) 1.31 (0.89, 1.94) 1.26 (0.85, 1.87) 1.79 (1.34, 2.38)
Bold indicates statistically significant results.
IDU injection drug use. cART combination antiretroviral therapy.
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urgent need for additional approaches concerning pre-
ventable bacterial infections, such as expansion of vaccin-
ation for influenza and pneumococcal disease.
Over the years, our study population aged significantly,
more likely as a result of patients living longer with
HIV/AIDS than of older patients reaching care. As a re-
sult, the incidence rate of severe morbid events associ-
ated with increased age, such as non-AIDS-defining
malignancies, cardiovascular diseases and other end-
organ diseases could be expected to increase with time.
Although improved management of traditional cardio-
vascular risk factors and the use of more lipid friendlier
ART regimens may have a favorable impact on the inci-
dence of cardiovascular events, the French hospital data-
base showed that HIV replication and immune status
are independent predictors of myocardial infarction in
HIV-infected individuals [24]. Further investigations
should look for optimal monitoring strategies for non-
AIDS co-morbidities in individuals on and off cART
both in high- and middle/low-income countries, espe-
cially among those aged 50 and above.
Hepatic failure secondary to viral hepatitis was the
most frequent hepatic event in our analysis. Other stud-
ies have demonstrated the increasing impact of chronic
viral hepatitis and liver disease on hospital admission
rates [22,25-27]. Prevention of hepatitis co-infection,
timely treatment of chronic viral hepatitis in HIV co-
infected patients, and careful monitoring of treatment
related hepatotoxicity are important measures to reduce
liver-related complications and subsequent hospitalizations.
In the present analysis severe morbidity requiring
hospitalization due to non-AIDS malignancies did not
show an increasing trend over time. Berry et al., in a
contemporary analysis (2001–2008), were also unable to
find an increase in hospitalizations for non-AIDS malig-
nancies [3]. In contrast, it was recently shown that the
relative frequency of deaths due to non-AIDS malignan-
cies have increased in France [28]. In addition, large epi-
demiological studies has shown an increased incidence
of non-AIDS malignancies in HIV-infected groups, two-
fold higher than that found in the general population
[29,30]. However, these latter studies included data up to
2002 and therefore did not take into account the long-
term benefit of cART. Other recent studies of cancer in-
cidence have reported increases in specific cancers (such
as anal cancer and Hodgkin Disease) but no clear in-
crease in overall non-AIDS malignancies since 2001
[31]. In our study, malignant neoplasm of the lung was
the most frequent diagnosis among the non-AIDS malig-
nancies category. As shown by several studies, the inci-
dence of this malignancy is increased with HIV infection
and even more so among patients with AIDS compared
to demographically similar populations [32-34]. It has
been suggested that immunodeficiency-induced recurrent
pneumonia and its associated inflammation may contrib-
ute to lung carcinogenesis in HIV infected individuals
[35]. Given the lack of effective treatment options and as
HIV-infected individuals live longer in the era of cART, it
is expected that smoking will increasingly manifest its
oncogenic potential and that lung cancer may become an
increasingly important cause of death. Tobacco cessation
programs already in place for the ANRS CO3 Aquitaine
Cohort, as well as in other settings, can help reduce lung
cancer incidence in this scenario [36,37].
Among the specific non-AIDS categories, our study
shows that psychiatric and neurologic diseases impose a
significant burden. Although the incidence rate of psy-
chiatric disease showed decreasing trends over the study
period, it was the second most frequent cause of severe
morbidity which shows the need for access to outpatient
psychiatric care and coverage of psychotropic medicines,
as well as careful monitoring of interactions between
cART, in particular of efavirenz [38] and psychiatric
medications. In our adjusted analyses we found that IDU
was significantly associated with a higher overall rate of
non-AIDS events, being most likely driven by psychiatric
and neurologic severe morbidity. In addition, ageing was
also found to be associated with neurologic diseases.
This finding, when coupled with the most frequent diag-
noses reported in the neurologic category (headache and
dizziness) suggests an increased rate of hospital admis-
sions for investigational purposes but without a concrete
discharge diagnosis.
The present study has important strengths and limita-
tions. This is the first study to compare causes of severe
morbidity from the Northern and Southern hemispheres.
In this study, a severe morbid event was defined as any
event associated with a hospitalization for at least
48 hours. Thus, the studied events were on the same
level of severity. In addition, both cohorts have reference
hospitals to which patients refer to for hospitalizations,
thus substantially decreasing the chances of missed hos-
pitalizations. On the other hand, by definition, severe
morbid events requiring hospitalization of less than
48 hours were excluded and thus it is possible that a
fraction of severe morbid events were not represented in
this study. Differently from Crum-Cianflone et al. [22],
where each hospitalization was placed into a single cat-
egory, we captured all diagnoses associated with a
hospitalization thus allowing for a more thorough de-
scription of the causes and trends of severe morbid
events. The present study did not explore the impact of
different cART regimens and further studies are needed
to evaluate the impact of different treatments (in par-
ticular of efavirenz-based treatments) on the overall and
specific non-AIDS severe morbidities [38]. The present
study sought to harmonize hospital discharge diagnoses of
two distinct hospital-based cohorts into comprehensive
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categories but decisions to group specific diagnoses in one
or another category were made arbitrarily and thus could
have influenced the results. As we move forward from
evaluating mortality alone to include morbidity, data
harmonization will become an increasing challenge. Fi-
nally, information on the presence of risk factors of severe
morbidity, such as tobacco use and alcohol consumption,
on important comorbidities as diabetes and hypertension,
on the use of preventive interventions such as vaccina-
tions, and on the use of treatment for other comorbidities
such hepatitis B/C infections were not taken into account
in this study as data was not systematically available. Ef-
forts should be made in all cohorts of HIV-infected indi-
viduals to improve the information collected concerning
these determinants.
Overall, our study shows that lower CD4 cell counts
led to a higher incidence rate of both AIDS-related and
non-AIDS-related events. Indeed, only 15% of the events
occurred in the CD4 stratum >500 cells/mm3. Several
studies have also noted the relationship between lower
CD4 counts and severe morbidity [8,22,26]. Higher
plasma HIV RNA and shorter time since first HIV posi-
tive test were significantly associated with a higher inci-
dence rate of severe morbidity. Late diagnosis is still a
major public health issue both in France and in Brazil
[39,40]. Our results emphasize the critical need for earl-
ier HIV diagnosis, linkage to care and prompt cART ini-
tiation to maintain robust CD4 counts to further reduce
morbidity and mortality. Non-AIDS severe morbidity
was associated with older age. Increasing age was also
associated with increased hospital admissions, especially
for non-AIDS causes in other studies [22]. Ageing of the
HIV population may be contributing to the high hos-
pitalization rates, a trend that will likely persist in the
upcoming years. Poly-pathology, which increases with
ageing, may also play a role [41,42].
Conclusions
In conclusion, our study shows improvements up until
2008 both in South Western France and the region of
Rio de Janeiro and allows the identification of priorities
for improving the quality of life of patients, beyond spe-
cific HIV treatment. Cohorts should increase efforts to
record and analyze non-AIDS severe morbidity both in
the North and the South, to better reflect the disease
burden of a chronic disease requiring life-long treatment
and grasp the future epidemiological trends as equally
and accurately as possible.
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